These results indicate that, in this model of breast cancer, the inhibition of p38 MAPK cooperates with cisplatin treatment to induce tumour cell death, which correlates with increased ROS and JNK pathway activation in the tumour cells. This evidence concerns the gene MAPK8 and breast carcinoma.